September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
December 2012 in “http://isrctn.org/>”
50 citations
,
July 2014 in “International Journal of Clinical Pharmacology and Therapeutics” New finasteride solution effectively reduces baldness-causing hormone, potentially with fewer side effects.
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
16 citations
,
June 2015 in “Drug Design Development and Therapy” The new formulation improves dutasteride's absorption when taken orally.
38 citations
,
February 2019 in “Clinical Interventions in Aging” Dutasteride more effectively treats hair loss than finasteride, but may increase risk of altered libido.
February 2021 in “Reactions Weekly” Finasteride and dutasteride may cause macular abnormalities.
June 2025 in “International Journal of Dermatology” 3 citations
,
November 1983 in “BMJ” 2 citations
,
April 1984 in “BMJ” 14 citations
,
March 2018 in “Current Drug Delivery” Topical finasteride can effectively treat male pattern baldness with fewer side effects than oral use.
August 2023 in “Journal of Investigative Dermatology” 20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
1 citations
,
January 2005 in “임상약리학회지” HDMHG0401-10 treatment significantly improved hair count and was better than a placebo in reducing hair loss in men with hereditary hair loss, with no major side effects.
March 2020 in “Case medical research”
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
January 2020 in “Journal of Clinical Dermatology” Dutasteride helps increase hair density in patients with female-pattern hair loss by activating a new growth mechanism.
3 citations
,
November 2005 in “Journal of Research in Medical Sciences” Finasteride cream didn't significantly reduce hair more than a placebo, but users felt it helped.
13 citations
,
February 2022 in “JAMA Dermatology” Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” February 2025 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
October 2024 in “JAAD Case Reports” Dutasteride mesotherapy showed mixed results and is not recommended as a primary treatment for hair loss.
October 2023 in “Georgetown medical review” Finasteride and Dutasteride can improve hair growth in male baldness but may cause temporary sexual dysfunction and possibly affect fertility.
Most patients were satisfied with topical finasteride, and few experienced side effects.
May 2018 in “Hair transplant forum international” Topical finasteride promotes hair growth with minimal side effects but needs more research for women and optimal use.
January 2024 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Combining minoxidil with dutasteride and microneedling is more effective for female pattern hair loss than just dutasteride and microneedling.